HealthTree for AML Radio: Gabriel Mannis, MD, Stanford Cancer Institute

Dr. Gabriel Mannis of the Stanford Cancer Institute is studying what could become the first all oral therapy for newly diagnosed AML. The combination of venetoclax and decitabine with cedazuridine (ASTX727) would provide older adults with AML and those who cannot tolerate standard intensive chemotherapy a much needed alternative treatment option.

Join us live on September 13th at 3 PM Central to learn more about this exciting clinical trial directly from the researcher himself!

Thank you to our episode sponsor, Bristol Myers Squibb.